Skip to main content
OpenTrials
Completed

NCT Number: NCT03896932

Minipooled-IVIG in Primary Immunodeficiency Disease

1. study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG) 2. Study the safety and efficacy of a newly developed preparation of MP-IVIG in children with primary immunodeficiency (PID) :

* Adverse reaction of MP-IVIG(anaphylaxis and haemolysis)( no or mild or moderate) * Prevention of severe bacterial infection * Improvement of general health(weight gain and mentality) * Integration in to social live 3. Compare the efficacy of MP-IVIG to standard IVIG in children with primary immunodeficiency (PID).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Primary Immunodeficiency Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Immune System Diseases Immunologic Deficiency Syndromes Primary Immunodeficiency Diseases

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of Medicine

Asyut, Egypt

About this study

Primary immunodeficiency diseases (PID) are a heterogeneous group of inherited disorders of the immune system, predisposing individuals to recurrent infections, allergy, autoimmunity, and malignancies. Clinical descriptions have already been made for more than 200 PIDs, for which over 150 forms of PID have been molecularly characterized .

A population prevalence of diagnosed PID in the United States at approximately 1 in 1,200 persons.

A part from local registration in some centres there is no national registry of PID in Egypt, and hence, the prevalence of these disorders in the investigator's population is still unknown .

An increasing number of PID are recognized, and effective treatments are possible. Early use of prophylactic antibiotics and replacement immunoglobulin can prevent significant end organ damage and improve long quality of life in these patients .

Immunoglobulin G (IgG) is an essential plasma derived medicine that is lacking in developing countries .IgG shortages leave immune deficient patients without treatment, exposing them to devastating recurrent infections from local pathogens. A simple and practical method for producing IgG from normal plasma collected in developing countries is needed to provide better, faster access to IgG for patients .

Magdy EL-Ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma processing methods implementable with minimum infrastructural requirements. They developed viral inactivation and protein purification technologies in single-use equipment to prepare virally safe solvent/detergent-filtered (S/D-F) plasma Producing a 90%pure immunoglobulin fraction in disposable single-use devices for transfusion as well as minipool S/D-F cryoprecipitate to treat bleeding disorders.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age group: children patients under 18 years.
  • The study will include patient diagnosed as primary immunodeficiency disease (PID) in Assiut university hospital on standard IVIG therapy.

Exclusion criteria

  • Patient has SCID.
  • Patient with history of severe IVIG side effect.
  • Patient with severe immunodeficiency and has severe disseminated infection.
  • Patient with renal impairment
  • Patient with hepatic cell failure
  • Patient with endocrinal abnormalities
  • patient with secondary immunodeficiency diseases

Treatment and study plan

minipooled- Intravenous immunoglobulin(MP-IVIG)

Other

The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.

Primary outcomes

  1. Efficacy of MP-IVIG assessed by the incidence of acute Serious Bacterial infections(SBIs)

    Time frame: 1 year

    The rate of Acute SBIs for each participant per 1 year will be assessed by questionnaire (Serious Bacterial Infections) include sign and symptoms of acute serious bacterial infections, i.e. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, osteomyelitis/ septic arthritis, visceral abscess.

  2. Safty of MP-IVIG assessed by percentage of adverse Events

    Time frame: 72 hour after adminstration of MP-IVIG and betwen infusions period

    Overall percentage of adverse events as hemolysis and anaphylaxis headache and other complains that occur during 72 hours of following an infusion of MP-IVIG will be assessed by1) vital sign(pulse,blood pressure,Respiratory rate and temprature 2)Hemolysis by hemoglobin level,LDH,billirubin level.2)lbetwen infusions by home diaries.

  3. Study the pharmacokinetics- MP-IVIG trough levels

    Time frame: predose sample

    MP-IVIG trough level concentration values of serum total IgG pre the MP-IVIG infusion

    (if applicable).

  4. Study the pharmacokinetics MP-IVIG plasma concentration -time curve

    Time frame: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose

    Blood samples for analysis of pharmacokinetics MP-IVIG plasma concentration -time curve were obtained and analysed

  5. Study the pharmacokinetics MP-IVIG half-life

    Time frame: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose

    Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed

  6. Study the pharmacokinetics MP-IVIG area under the curve

    Time frame: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose

    Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed

  7. Study the pharmacokinetics MP-IVIG Cmax

    Time frame: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose

    Blood samples for analysis of pharmacokinetics MP-IVIG Cmax were obtained and analysed

  8. Study the pharmacokinetics of MP-IVIG-Tmax.

    Time frame: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose

    Blood samples for analysis of pharmacokinetics MP-IVIG Tmax were obtained and analysed

  9. Study the pharmacokinetics of MP-IVIG elimination rate constant(s).

    Time frame: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose

    Blood samples for analysis of pharmacokinetics MP-IVIG elimination rate constant(s) were obtained and analysed

Secondary outcomes

  1. Compare efficacy of MP-IVIG vs standard IVIG by compare incidence of SBIs of both

    Time frame: 1 year

    • Compare the efficacy of MP-IVIG to standard IVIG in children with Primary immunodeficiency disease (PID).

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Study of Safety and Efficacy of Mini-pool Intravenous Immunoglobulin (MP-IVIG) Prepared by Assiut University Hospital Blood Bank in Primary Immunodeficiency Patients

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 1, 2019
Registry last updated
May 12, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.